Influenza causes epidemics of respiratory infection in young children each winter. Young children, particularly those under 6 months of age are most vulnerable to suffering from complications secondary to influenza infection. Consequently, influenza vaccine has been recommended for children 6-59 months of age. Influenza vaccine is not approved for use in children under 6 month of age who are at...
Date First Received: December 7, 2007
Last Updated: May 4, 2008
Verified by: Duke University, May 2008
Clinical Trial Phase: N/A | Start Date: October 2007
Overall Status: Completed
Estimated Enrollment: 600
Brief Summary
Official Title: “Prevention of Influenza in Infants by Immunization of Their Contacts in the Household”
Condition Keyword(s):
Intervention(s):
Influenza causes epidemics of respiratory infection in young children each winter. Young children, particularly those under 6 months of age are most vulnerable to suffering from complications secondary to influenza infection. Consequently, influenza vaccine has been recommended for children 6-59 months of age. Influenza vaccine is not approved for use in children under 6 month of age who are at highest risk. Therefore, the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices has recommended vaccination of household contacts of children under 6 month of age - a cocooning strategy.
The current study is a hospital-based study to assess the effectiveness of a program to vaccinate birth mothers and household contacts of newborns with influenza vaccine. We propose to study both birth mothers and household contacts of newborns delivered at Durham Regional Hospital and Duke University Medical Center, birthing hospitals serving Durham and surrounding counties in central North Carolina. We will implement several strategies to increase vaccine coverage rates at Durham Regional Hospital utilizing Duke University Hospital as a control setting. Strategies will include: standing vaccine orders for birth mothers, vaccine reminders for household contacts, and a hospital based influenza vaccine clinic to increase vaccine accessibility for household contacts. Vaccine coverage rates will be assessed utilizing a survey method and self report of the birth mothers. We hypothesize that influenza vaccine coverage rates for new mothers and household contacts of newborns delivered at the intervention hospital will be higher when compared to coverage rates in the control hospital. Demographic determinants of vaccine coverage and reasons for refusal of influenza vaccine will also be assessed.
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Parallel Assignment
Intervention(s) in this Clinical Trial
- Biological: Trivalent inactivated influenza vaccine
- Standing postpartum vaccine orders, influenza vaccine clinic on postpartum ward for household contacts, mailed vaccine reminders
- Other: Control
- Control, usual care
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: 1
- Intervention Hospital
- No Intervention: 2
- Control Hospital
Outcome Measures for this Clinical Trial
Primary Measures
- Influenza vaccine coverage rates for new mothers and household contacts of newborns
- Time Frame: Pregnancy through 6 weeks postpartum
Safety Issue?: No
- Time Frame: Pregnancy through 6 weeks postpartum
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Mother of a newborn delivered at either Durham Regional Hospital or Duke University
- Hospital between October 2007 and February 2008
Exclusion Criteria:
- Fetal demise or stillbirth
- Maternal rights relinquished
- Language barrier
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Duke University
Overall Clinical Trial Officials and Contacts
Emmanuel B Walter, MD, MPH Principal Investigator Duke University Health System
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00570037
Study ID Number: 9436-07-2R0ER
ClinicalTrials.gov Identifier: NCT00570037
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.